Additionally, we performed sensitivity analyses to evaluate how varying the reduction in body weight to lower (8%) and higher (12%) effectiveness of GLP-1 RA therapy in the real-world would impact the estimates of preventable obesity-related cancers in Canada. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.